Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study
8 May, 2020Mortality of patients with coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome
(ARDS), and systemic inflammation is high. In areas of pandemic outbreak, the number of patients can exceed
maximum capacity of intensive care units (ICUs), and, thus, these individuals often receive non-invasive ventilation
outside of the ICU. Effective treatments for this population are needed urgently. Anakinra is a recombinant interleukin-1
receptor antagonist that might be beneficial in this patient population.
